David A. Proia

4.3k total citations
57 papers, 2.6k citations indexed

About

David A. Proia is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, David A. Proia has authored 57 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 12 papers in Oncology and 8 papers in Genetics. Recurrent topics in David A. Proia's work include Heat shock proteins research (37 papers), ATP Synthase and ATPases Research (12 papers) and Computational Drug Discovery Methods (7 papers). David A. Proia is often cited by papers focused on Heat shock proteins research (37 papers), ATP Synthase and ATPases Research (12 papers) and Computational Drug Discovery Methods (7 papers). David A. Proia collaborates with scholars based in United States, Germany and United Kingdom. David A. Proia's co-authors include Richard C. Bates, Charlotte Kuperwasser, Jim Sang, Suqin He, Donald L. Smith, Manuel Sequeira, Chaohua Zhang, Jaime Acquaviva, Yumiko Wada and Matthias Dobbelstein and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

David A. Proia

57 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Proia United States 30 1.9k 945 376 362 323 57 2.6k
Marzia Pennati Italy 32 2.4k 1.3× 906 1.0× 365 1.0× 735 2.0× 327 1.0× 64 3.4k
Parthasarathy Seshacharyulu United States 29 1.7k 0.9× 1.1k 1.2× 421 1.1× 595 1.6× 435 1.3× 53 2.9k
Harshani R. Lawrence United States 35 2.1k 1.1× 1.3k 1.4× 286 0.8× 283 0.8× 683 2.1× 75 3.5k
Antonella Papa United States 18 2.4k 1.3× 855 0.9× 390 1.0× 560 1.5× 247 0.8× 29 3.1k
Kenneth Kolinsky United States 19 1.3k 0.7× 1.3k 1.3× 350 0.9× 294 0.8× 326 1.0× 33 2.3k
Igor Astsaturov United States 32 1.2k 0.7× 1.1k 1.2× 496 1.3× 512 1.4× 339 1.0× 97 2.7k
Sabina Cosulich United Kingdom 26 2.0k 1.0× 526 0.6× 290 0.8× 336 0.9× 253 0.8× 55 2.6k
Takehiko Dohi United States 22 2.7k 1.5× 793 0.8× 205 0.5× 464 1.3× 477 1.5× 39 3.3k
Matthew R. Janes United States 15 2.2k 1.2× 594 0.6× 251 0.7× 273 0.8× 285 0.9× 26 2.7k
T. Khanh United States 26 1.6k 0.9× 991 1.0× 462 1.2× 473 1.3× 238 0.7× 57 2.5k

Countries citing papers authored by David A. Proia

Since Specialization
Citations

This map shows the geographic impact of David A. Proia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Proia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Proia more than expected).

Fields of papers citing papers by David A. Proia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Proia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Proia. The network helps show where David A. Proia may publish in the future.

Co-authorship network of co-authors of David A. Proia

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Proia. A scholar is included among the top collaborators of David A. Proia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Proia. David A. Proia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomenius, Michael J., Jason K. Kirby, Roman V. Agafonov, et al.. (2023). CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents. Hematological Oncology. 41(S2). 550–551. 4 indexed citations
2.
Agafonov, Roman V., Prasoon Chaturvedi, Scott J. Eron, et al.. (2022). CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents. Blood. 140(Supplement 1). 11575–11575. 1 indexed citations
3.
Agafonov, Roman V., Lydia M. Emerson, Marta Isasa, et al.. (2021). A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination. SLAS DISCOVERY. 26(4). 547–559. 9 indexed citations
4.
London, Cheryl A., Jaime Acquaviva, Donald L. Smith, et al.. (2018). Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors. Clinical Cancer Research. 24(24). 6396–6407. 8 indexed citations
5.
Nikonova, Anna S., Alexander Y. Deneka, Meghan C. Kopp, et al.. (2016). A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer. Clinical Cancer Research. 22(20). 5120–5129. 25 indexed citations
6.
Wang, Yifan, Hui Liu, Lixia Diao, et al.. (2016). Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clinical Cancer Research. 22(23). 5876–5886. 27 indexed citations
7.
Proia, David A., Donald L. Smith, Junyi Zhang, et al.. (2015). HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors. Molecular Cancer Therapeutics. 14(11). 2422–2432. 29 indexed citations
8.
Acquaviva, Jaime, Donald L. Smith, John-Paul Jimenez, et al.. (2014). Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib. Molecular Cancer Therapeutics. 13(2). 353–363. 79 indexed citations
9.
Acquaviva, Jaime, Suqin He, Chaohua Zhang, et al.. (2014). FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism. Molecular Cancer Research. 12(7). 1042–1054. 57 indexed citations
10.
Acquaviva, Jaime, Suqin He, Jim Sang, et al.. (2014). mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis. Molecular Cancer Research. 12(5). 703–713. 40 indexed citations
11.
Friedland, Julie C., Donald L. Smith, Jim Sang, et al.. (2013). Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. Investigational New Drugs. 32(1). 14–24. 46 indexed citations
12.
Sang, Jim, Jaime Acquaviva, Julie C. Friedland, et al.. (2013). Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Cancer Discovery. 3(4). 430–443. 174 indexed citations
13.
Seeger‐Nukpezah, Tamina, David A. Proia, Brian L. Egleston, et al.. (2013). Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease. Proceedings of the National Academy of Sciences. 110(31). 12786–12791. 37 indexed citations
14.
Liu, Hanqing, Ilya G. Serebriiskii, Shane W. O’Brien, et al.. (2013). Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer. Clinical Cancer Research. 19(18). 5053–5067. 41 indexed citations
15.
Proia, David A., Chaohua Zhang, Manuel Sequeira, et al.. (2013). Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer. Clinical Cancer Research. 20(2). 413–424. 53 indexed citations
16.
Nagaraju, Ganji Purnachandra, Wungki Park, Jing Wen, et al.. (2013). Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis. 16(4). 903–917. 71 indexed citations
17.
Acquaviva, Jaime, Donald L. Smith, Jim Sang, et al.. (2012). Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib. Molecular Cancer Therapeutics. 11(12). 2633–2643. 83 indexed citations
18.
Ying, Weiwen, Zhenjian Du, Lijun Sun, et al.. (2011). Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy. Molecular Cancer Therapeutics. 11(2). 475–484. 181 indexed citations
19.
Gupta, Piyush B., David A. Proia, Oya Cingöz, et al.. (2007). Systemic Stromal Effects of Estrogen Promote the Growth of Estrogen Receptor–Negative Cancers. Cancer Research. 67(5). 2062–2071. 138 indexed citations
20.
Proia, David A. & Charlotte Kuperwasser. (2005). Stroma: Tumor Agonist or Antagonist. Cell Cycle. 4(8). 1022–1025. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marzia Pennati Breakdown of academic impact, for papers by Parthasarathy Seshacharyulu Breakdown of academic impact, for papers by Harshani R. Lawrence Breakdown of academic impact, for papers by Antonella Papa Breakdown of academic impact, for papers by Kenneth Kolinsky Breakdown of academic impact, for papers by Igor Astsaturov Breakdown of academic impact, for papers by Sabina Cosulich Breakdown of academic impact, for papers by Takehiko Dohi Breakdown of academic impact, for papers by Matthew R. Janes Breakdown of academic impact, for papers by T. Khanh
Rankless by CCL
2026